rep 2139
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT02646189)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rep 2139
- rep 2139-ca
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02565719 | Phase 2 | Mar 1, 2016 | Replicor Inc., State University of Medicine and Pharmacy, Moldova |
| NCT02233075 | Phase 2 | Sep 1, 2014 | Replicor Inc. |
| NCT02726789 | Phase 2 | Oct 1, 2012 | Bangladesh Medical University, Replicor Inc. |
| NCT02646189 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Bangladesh Medical University, Replicor Inc. |
| NCT05683548 | N/A | — | Replicor Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Replicor Inc. | For profit | 5 | 5 | 2 | 2011 |
| Bangladesh Medical University | Academic/Hospital | 2 | 0 | 1 | 2011 |
| State University of Medicine and Pharmacy, Moldova | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1